metaPreg - Fluvoxamine during pregnancy

Fluvoxamine updated on 10-20-2025

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	0.77 [0.48, 1.25]	0%	5 studies	116,016	519	not evaluable	ROB	-
Major congenital malformations	0.75 [0.45, 1.24]	0%	4 studies	74,781	481	not evaluable	ROB	-
Congenital heart defects	1.15 [0.49, 2.69]	0%	3 studies	8,651	414	not evaluable	ROB	-
Limb defects	0.83 [0.31, 2.23]	0%	2 studies		295	not evaluable	ROB	-
Nervous system anomalies	2.37 [0.75, 7.46]	0%	2 studies		295	not evaluable	ROB	-
Atrial septal defect	1.02 [0.06, 16.42]	-	1 study	1,279	240	not evaluable	ROB	-
Cardiac septal defects	2.10 [0.51, 8.68]	-	1 study		55	not evaluable	ROB	-
Digestive system anomalies	1.35 [0.19, 9.62]	-	1 study		240	not evaluable	ROB	-
Respiratory system anomalies	2.86 [0.39, 20.85]	-	1 study		240	not evaluable	ROB	-
Transposition of the great vessels	5.50 [0.34, 88.45]	-	1 study	238	240	not evaluable	ROB	-
Ventricular septal defect	0.42 [0.06, 2.97]	-	1 study	5,466	240	not evaluable	ROB	-
Maternal consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Gestational diabetes	1.01 [0.50, 2.04]	-	1 study	20,905	78	not evaluable	ROB	-
Preeclampsia	1.71 [0.20, 14.61]	-	1 study	1,216		not evaluable	ROB	-
Neonatal disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Neonatal death (< 28 days of life)	-	-	0 study					-
Persistent pulmonary hypertension	3.68 [0.23, 59.14]	-	1 study	1,935	112	not evaluable	ROB	-
Long term consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Child/Infant death (> 28 days of life)	1.89 [0.60, 5.95]	-	1 study			not evaluable	ROB	-
Intrauterine deaths
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Early intrauterine deaths (< 22 weeks) / Spontaneous abortions	2.36 [0.94, 5.95]	0%	2 studies	5,134	9	not evaluable	ROB	-
Late intrauterine deaths (> 22 weeks) / Stillbirths	-	-	0 study					-
Neuro-developmental disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
ASD (Autism spectrum disorder): Diagnosis	7.30 [0.30, 177.69]	-	1 study	1,005	35	not evaluable	ROB	-
ASD (Autism spectrum disorder): Diagnosis/Risk	7.30 [0.30, 177.69]	-	1 study	1,005	35	not evaluable	ROB	-
Cognitive developmental disorders/delay (3-6 years old)	-	-	0 study					-
Hide endpoints reported in only one study ...